Immutep Gets Positive Feedback From FDA On Late-Stage Clinical Development Of Eftilagimod Alfa
5/8 18:37
(RTTNews) - Immutep Limited (IMMP), a late-stage immunotherapy company targeting cancer and autoimmune diseases, Tuesday announced it has received positive and constructive feedback from the US Food and Drug Administration (FDA), regarding future clinical development of its first...